Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC17H18Cl2N2O2S |
InChIKeyQIRSWHWANMQORU-UHFFFAOYSA-N |
CAS Registry2892720-11-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CN | 27 Jul 2024 |